Index

Note: Page numbers of article titles are in **boldface** type.

A

Adjuvant therapy, for penile cancer, 466–467
Anatomy, of urologic lymphadenectomy, **375–386**
  embryology of lymphatic system, 376
  for bladder malignancies, 378–379
  for kidney malignancies, 377–378
    renal cell carcinoma, 421–422
  for penile malignancies, 381–383, 459
  for prostate malignancies, 379–380
  for testicular malignancies, 380–381
  for upper tract urothelial carcinoma, 429–430
Androgen deprivation therapy, adjuvant, for pT3 prostate cancer, 392–393
Antibiotics, prophylactic, for inguinal lymph node dissection, 509–510

B

Biopsy, dynamic sentinel node, in penile cancer, 463
Bladder, anatomy of lymphatic drainage of, 511
Bladder cancer, feasibility of minimally invasive lymphadenectomy in, **407–418**
  in radical cystectomy, 410–417
    early experience with, 410–412
    robotic approaches, 412–417
  lymphadenectomy for, **397–405**
    anatomy and history of, 378–379
    controversies, 397–403
      adequate template for PLND, 398–399
      impact of PLND on prognosis and outcome, 400–403
      importance of number of nodes removed, 400
      terminology, 397–398
      value of technetium-based mapping study, 399–400
    indications, 397
  pathologic considerations in lymphadenectomy for, 486–488
  pelvic lymphadenectomy in, and survival, 511–512
  radiation therapy of lymph nodes in, 501
Bowel complications, of retroperitoneal lymphadenectomy, 515

C

Complications, of lymphadenectomy in urologic surgery, **507–518**
  of LND in upper tract urothelial carcinoma, 435
  of RPLND for testicular cancer, 445–446
  with inguinal lymph node dissection, 507–510
    lymphedema, 508–509
    prevention of, 509–510
    relevant surgical anatomy, 508
    skin flap necrosis, 509
    wound infection, 508
  with pelvic lymph node dissection, 510–514
    anatomy of lymphatic drainage of bladder, 511
    in bladder cancer, 511–512
    lymphoceles, 512–513
    nerve injury, 513–514
    ureteral injury, 513
    with radical cystectomy, 511
    with radical prostatectomy, 510–511
  with retroperitoneal lymph node dissection, 514–516
    bowel, 515
    ejaculatory dysfunction, 515
    lymphatic dysfunction, 515
    vascular, 514–515
Computed tomography (CT), in penile cancer, 460
  single-photon emission (SPECT), for lymph node imaging in urologic oncology, 473–474
Cystectomy, radical, complications of pelvic lymph node dissection in, 511
  radical, feasibility of minimally invasive lymphadenectomy in, **407–418**
    early experience with, 410–412
    robotic approaches, 412–417
      extended nodal dissection in, 413
      issues of learning curve, 413–415
      technique of, 415–417
Cytology, fine-needle aspiration, ultrasound with, for penile cancer assessment, 460

D

Deep vein thrombosis, prophylaxis for, in inguinal lymph node dissection, 510
Diffusion-weighted magnetic resonance imaging (DW-MRI), for lymph node imaging in urologic oncology, 477–478
Dynamic sentinel node biopsy, in penile cancer, 463

E

Ejaculatory dysfunction, as complication of retroperitoneal lymphadenectomy, 515

Urol Clin N Am 38 (2011) 519–523
doi:10.1016/S0094-0143(11)00104-2
0094-0143/11/$ – see front matter

© 2011 Elsevier Inc. All rights reserved.

urologic.theclinics.com

Embryology, of the lymphatic system, 376
Extended lymph node dissection (ELND), for prostate cancer, drawbacks of, 391–392
evidence for improved staging with, 388–389
for high-risk disease, 408–409
potential therapeutic effect of, 390–391

G

Germ cell tumors, of the testis, 439

H

History, of urologic lymphadenectomy, **375–386**
embryology of lymphatic system, 376
for bladder malignancies, 378–379
for kidney malignancies, 377–378
for penile malignancies, 381–383
for prostate malignancies, 379–380
for testicular malignancies, 380–381
of lymphatic system, 375–376
of surgical lymphadenectomy, 376–377

I

Imaging, of lymph nodes, novel modalities in urologic oncology, **471–481**
diffusion-weighted magnetic resonance imaging (DW-MRI), 477–478
in penile cancer, 460–461
lymphotropic nanoparticle-enhanced magnetic resonance imaging (LN-MRI), 474–477
positron emission tomography (PET), 471–473
sentinel lymph node imaging, 478–479
single-photon emission computed tomography (SPECT), 473–474
Inguinal lymph node dissection, complications of, in urologic surgery, 507–510
lymphedema, 508–509
prevention of, 509–510
relevant surgical anatomy, 508
skin flap necrosis, 509
wound infection, 508
in penile cancer, 463–465
indications for, 463–464
surgical aspects of, 464–465

K

Kidney cancer. *See also* Renal cell carcinoma.
anatomy and history of lymphadenectomy for, 377–378
pathologic considerations in lymphadenectomy, 485–486

L

Laparoscopic procedures, prostatectomy, lymphadenectomy in, 409
RPLND for testicular cancer, 445, **451–458**
Lymph node dissection (LND). *See* Lymphadenectomy.
Lymph nodes. *See also* Lymphadenectomy.
in urologic malignancies, modalities for lymph node imaging in, **471–481, 497–506**
novel modalities for imaging, **471–481**
radiation therapy for, **497–506**
Lymphadenectomy, in urologic oncology, 375–518
complications of, **507–518**
for bladder cancer, **397–405**
for penile cancer, **459–469**
for prostate cancer, **387–395**
for renal cell carcinoma, **419–428**
for testicular cancer, **439–449**
for upper tract urothelial carcinoma, **429–437**
history and anatomy of, **375–386**
embryology of lymphatic system, 376
for bladder malignancies, 378–379
for kidney malignancies, 377–378
for penile malignancies, 381–383
for prostate malignancies, 379–380
for testicular malignancies, 380–381
history of lymphatic system, 375–376
history of surgical lymphadenectomy, 376–377
minimally invasive, **407–418, 451–458**
feasibility in bladder and prostate cancer, **407–418**
for testicular cancer, **451–458**
pathologic considerations, **483–495**
Lymphatic complications, of retroperitoneal lymphadenectomy, 516
Lymphatic system. *See also* Lymph nodes.
embryology of, 376
history of, 375–376
Lymphedema, of complication of inguinal lymph node dissection, 508–509
Lymphoceles, as complication of pelvic lymphadenectomy, 512–513
Lymphotropic nanoparticle-enhanced magnetic resonance imaging (LN-MRI), for lymph node imaging in urologic oncology, 473–474

M

Magnetic resonance imaging, for lymph node imaging in urologic oncology, diffusion-weighted, 477–478
in penile cancer, 460–461
lymphotropic nanoparticle-enhanced, 474–477
Minimally invasive lymphadenectomy, feasibility of, **407–418**
in bladder cancer, 410–417
in radical cystectomy, 410–412
robotic approaches, 412–417
in prostate cancer, 408–410

extended lymphadenectomy for high-risk disease, 408–409
in laparoscopic prostatectomy, 409
in robotic prostatectomy, 409–410
overall decline in lymphadenectomy for, 408
retroperitoneal, in testicular cancer, **451–458**
complications, 456–457
indications, 452–453
preparation for, 453–454
results, 456
techniques, 454–456

N

Necrosis, skin flap, of complication of inguinal lymph node dissection, 509
Nephroureterectomy, open *versus* laparoscopic, 435
Nerve injury, as complication of pelvic lymphadenectomy, 513–514

O

Outcome, of bladder cancer, impact of PLND on, 400–403
of upper tract urothelial carcinoma, effects of LND on, 431–435

P

Pathology, with lymphadenectomy in urologic oncology, **483–495**
future considerations, 491–492
kidney, 485–486
penis, 490–491
prostate, 488–490
specimen submission and processing, 483–485
testes, 490
upper urinary tract and bladder, 486–488
Pelvic lymph node dissection (PLND). *See also* Lymphadenectomy.
complications of, in urologic surgery, 510–514
anatomy of lymphatic drainage of bladder, 511
in bladder cancer, 511–512
lymphoceles, 512–513
nerve injury, 513–514
ureteral injury, 513
with radical cystectomy, 511
with radical prostatectomy, 510–511
for bladder cancer, **397–405**
for penile cancer, 464, 465
for prostate cancer, **387–395**
Penile cancer, lymphadenectomy in, **459–469**
anatomy and history of, 381–383
anatomy of inguinal lymph nodes, 459
assessment of inguinal lymph nodes, 459–460
clinical examination, 460
complications of, 465–466
imaging, 460–461
CT, 460
MRI, 460–461
PET/CT scan, 461
ultrasound with fine-needle aspiration cytology, 460
in patients with CN+ disease, 462
in patients with CN0 disease, 461–462
close surveillance, 462
minimally invasive staging techniques, 462–463
predictive nomogram for occult metastases, 462
inguinal, indications for, 463–464
surgical aspects of, 464–465
investigations, 460
pelvic, indications for, 464
surgical aspects of, 465
prognosis and adjuvant treatment, 466–467
pathologic considerations for lymphadenectomy in., 490–491
radiation therapy of lymph nodes in, 502 = 503
Positron emission tomography (PET), for lymph node imaging in urologic oncology, 471–473
in penile cancer, 461
Prognosis, of bladder cancer, impact of PLND on, 400–403
of penile cancer, adjuvant treatment and, 466–467
Prostate cancer, lymphadenectomy for, **387–395**
adjuvant androgen deprivation therapy and, 392–393
adjuvant radiation therapy and, 392–393
current recommendations for patient selection and extent of pelvic, 393
drawbacks of extended, 391–392
evidence for improved staging by extended lymph node dissection, 388–389
history and anatomy of, 379–380
low-risk population that can avoid a, 389–390
potentially therapeutic, 390–391
minimally invasive lymphadenectomy for, **407–418**
extended lymphadenectomy for high-risk diseases, 408–409
lymphadenectomy in laparoscopic prostatectomy, 409
lymphadenectomy in robotic prostatectomy, 409–410
overall decline in lymphadenectomy for, 408
role of lymph node dissection in, 408
pathologic considerations for lymphadenectomy in., 488–490
radiation therapy of lymph nodes in, 499–501
elective coverage of regional nodes, 499–500
postoperative, 500–501

Prostatectomy, laparoscopic, lymphadenectomy in, 409
radical, complications of pelvic lymph node dissection in, 510–511
robotic, lymphadenectomy in, 409–410

R

Radiation therapy, role for treatment of lymph nodes in urologic malignancies, **497–506**
adjuvant, for pT3 prostate cancer, 392–393
basic principles, 497–499
charged particles, 498–499
external beam, 497–498
intensity modulated, 498
target volume and dose, 499
toxicity related to, 499
for bladder cancer, 501
for penile cancer, 502–503
for prostate cancer, 499–501
elective coverage of regional nodes, 499–500
postoperative, 500–501
for testicular cancer, 501–502
radiation dose, 502
target for adjuvant radiation, 502
site-specific discussion, 499–503
Radical cystectomy. *See* Cystectomy.
Radical prostatectomy. See Prostatectomy.
Renal cell carcinoma, role of lymph node dissection in, **419–428**
anatomy and templates, 421–422
morbidity and technique, 422
prospective evidence, 419–420
protocols and nomograms for predicting LN+ disease, 422–424
staging, 420–421
therapeutic role of, 424–426
in high-risk localized, 424–425
in low-risk localized, 424
in M1 disease, 425–426
in salvage RPLND, 425
Retroperitoneal lymph node dissection (RPLND), complications of, in urologic surgery, 514–516
bowel, 515
ejaculatory dysfunction, 515
lymphatic dysfunction, 515
vascular, 514–515
for testicular cancer, **439–449**
minimally invasive, **451–458**
Robotic prostatectomy, lymphadenectomy in, 409–410
Robotic-assisted radical cystectomy, in bladder cancer, 412–417
issues of learning curve, 413–415
techniques of robotic lymph node dissection, 415–417

S

Sentinel lymph node imaging, in urologic oncology, 478–479
Sentinel node biopsy, dynamic, in penile cancer, 463
Single-photon emission computed tomographic images (SPECT), for lymph node imaging in urologic oncology, 473–474
Skin flap necrosis, of complication of inguinal lymph node dissection, 509
Staging, in CN0 penile cancer, minimally invasive strategies for, 462–463
dynamic sentinel node biopsy, 463
modified inguinal lymphadenectomy, 462–463
in upper tract urothelial carcinoma, improved with lymphadenectomy, 420–421
of renal cell carcinoma, role of lymph node dissection in, 420–421
pathologic considerations in lymphadenectomy in urologic oncology, **483–495**
Survival. *See* Outcome.

T

Technetium-based mapping, and template for PLND for bladder cancer, 399–400
Templates, for LND for renal cell carcinoma, 421–422
for PLND for bladder cancer, 398–399
Testes, anatomy and history of lymphadenectomy for, 380–381
pathologic considerations for lymphadenectomy in, 490
Testicular cancer, minimally invasive retroperitoneal lymph node dissection for, **451–458**
complications, 456–457
indications, 452–453
laparoscopic access, 454
operating room setup, 453
patient positioning, 453–454
postoperative care, 456
preparation, 453
results, 456
technique for left template dissection, 455–456
techniques for right template dissection, 454–455
radiation therapy of lymph nodes in, 501–502
role of lymphadenectomy in, **439–449**
complications of, 445–446
controversies in, 443–445
development of contemporary RPLND, 439–441
germ cell tumors, 439
indications for RPLND, 441–443
Therapeutic role, of lymph node dissection, in renal cell carcinoma, 424–426
potential, for prostate cancer, 390–391

U

Ultrasound, with fine-needle aspiration cytology for penile cancer assessment, 460
Upper urinary tract, pathologic considerations for lymphadenectomy in., 486–488
  urothelial carcinoma, emerging role of lymphadenectomy in., **429–437**
Ureteral injury, as complication of pelvic lymphadenectomy, 513
Urologic oncology, lymphadenectomy in. *See also* Lymphadenectomy.
  novel imaging modalities for lymph nodes in, **471–481**
    diffusion-weighted magnetic resonance imaging (DW-MRI), 477–478
    lymphotropic nanoparticle-enhanced magnetic resonance imaging (LN-MRI), 474–477
    positron emission tomography (PET), 471–473
    sentinel lymph node imaging, 478–479
    single-photon emission computed tomography (SPECT), 473–474
Urothelial carcinoma, upper tract, emerging role of lymphadenectomy in, **429–437**
  anatomy, 429–430
  complications, 435
  effects on survival, 431–435
  improved staging, 430
  local control/nodal relapse, 430–431
  open *versus* laparoscopic, 435

V

Vascular complications, of retroperitoneal lymphadenectomy, 514–515
Venous thromboembolism, prophylaxis for, in inguinal lymph node dissection, 510

W

Wound infection, as complication of inguinal lymph node dissection, 508